journal
MENU ▼
Read by QxMD icon Read
search

Gastric Cancer

journal
https://www.readbyqxmd.com/read/28634748/exposure-response-relationship-of-ramucirumab-in-east-asian-patients-from-rainbow-a-randomized-clinical-trial-in-second-line-treatment-of-gastric-cancer
#1
Tae You Kim, Chia-Jui Yen, Salah-Eddin Al-Batran, David Ferry, Ling Gao, Yanzhi Hsu, Rebecca Cheng, Mauro Orlando, Atsushi Ohtsu
BACKGROUND: Ramucirumab is a recombinant human IgG1 neutralizing monoclonal antibody specific for vascular endothelial growth factor receptor-2. Second-line ramucirumab, in conjunction with paclitaxel (ramucirumab 8 mg/kg or placebo in combination with 80 mg/m(2) paclitaxel), has been shown to be effective and safe in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma in RAINBOW, a global phase III randomized clinical trial. We conducted an exploratory exposure-response analysis of efficacy and safety of ramucirumab in East Asian patients from the RAINBOW trial...
June 20, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28623524/does-a-laparoscopic-approach-attenuate-the-body-weight-loss-and-lean-body-mass-loss-observed-in-open-distal-gastrectomy-for-gastric-cancer-a-single-institution-exploratory-analysis-of-the-jcog-0912-phase-iii-trial
#2
Toru Aoyama, Tsutomu Sato, Tsutomu Hayashi, Takanobu Yamada, Haruhiko Cho, Takashi Ogata, Koji Oba, Takaki Yoshikawa
BACKGROUND: Laparoscopy-assisted distal gastrectomy (LADG) for gastric cancer may prevent the loss of body weight and lean body mass resulting from reduced surgical stress in comparison to open distal gastrectomy (ODG). A multicenter phase III trial conducted by the Japan Clinical Oncology Group (JCOG0912 trial) was performed to confirm the non-inferiority of LADG to ODG for stage I gastric cancer in terms of relapse-free survival. METHODS: This study was performed as a single-institution exploratory analysis using the data of the patients from our hospital who were enrolled in the JCOG0912 phase III trial...
June 16, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28616743/the-long-term-survival-of-stage-iv-gastric-cancer-patients-with-conversion-therapy
#3
Kazuya Yamaguchi, Kazuhiro Yoshida, Toshiyuki Tanahashi, Takao Takahashi, Nobuhisa Matsuhashi, Yoshihiro Tanaka, Kazuaki Tanabe, Hideki Ohdan
PURPOSE: A retrospective study was performed to clarify the role of conversion therapy (surgery with a prospect of R0 resection performed in initially unresectable metastatic cancer that responded to the chemotherapy) in stage IV gastric cancer (GC). PATIENTS AND METHODS: We treated 259 stage IV GC patients with systemic chemotherapy at Gifu and Hiroshima University Hospitals between 2001-2013. Of these, 84 patients who were subsequently treated by surgery were classified into four categories according to our previously published classification of stage IV GC, and short- and long-term outcomes were analyzed...
June 14, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28612219/prospective-phase-ii-study-evaluating-the-efficacy-of-swallow-ability-screening-tests-and-pneumonia-prevention-using-a-team-approach-for-elderly-patients-with-gastric-cancer
#4
Yuichiro Miki, Rie Makuuchi, Shinsaku Honda, Masanori Tokunaga, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Takashi Yurikusa, Akira Tanuma, Masanori Terashima
BACKGROUND: Aging partly impairs swallowing function, which is considered a risk factor for postoperative pneumonia (PP). We evaluated the efficacy of a new team-based strategy to reduce the incidence of PP in elderly patients with gastric cancer. METHODS: This single-center, prospective phase II study included elderly patients (≥75 years old) with gastric cancer undergoing gastric surgery. The primary endpoint was the incidence of Clavien-Dindo grade II or higher PP...
June 13, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28597328/the-comprehensive-complication-index-cci-is-a-more-sensitive-complication-index-than-the-conventional-clavien-dindo-classification-in-radical-gastric-cancer-surgery
#5
Tae-Han Kim, Yun-Suhk Suh, Yeon-Ju Huh, Young-Gil Son, Ji-Ho Park, Jun-Young Yang, Seong-Ho Kong, Hye Seong Ahn, Hyuk-Joon Lee, Ksenija Slankamenac, Pierre Alain Clavien, Han-Kwang Yang
BACKGROUND: The comprehensive complication index (CCI) integrates all complications of the Clavien-Dindo classification (CDC) and offers a metric approach to measure morbidity. The aim of this study was to evaluate the CCI at a high-volume center for gastric cancer surgery and to compare the CCI to the conventional CDC. METHODS: Clinical factors were collected from the prospective complication data of gastric cancer patients who underwent radical gastrectomy at Seoul National University Hospital from 2013 to 2014...
June 8, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28584890/survival-benefit-of-d2-plus-gastrectomy-in-gastric-cancer-patients-with-duodenal-invasion
#6
Koshi Kumagai, Takeshi Sano, Naoki Hiki, Souya Nunobe, Masahiro Tsujiura, Satoshi Ida, Manabu Ohashi, Toshiharu Yamaguchi
BACKGROUND: The optimal extent of lymph node (LN) dissection for gastric cancer with duodenal invasion is yet to be clarified. This study sought to evaluate the significance of gastrectomy with D2-plus lymphadenectomy including posterior LNs along the common hepatic artery (no. 8p), hepatoduodenal ligament LNs along the bile duct (no. 12b) and those behind the portal vein (no. 12p), LNs on the posterior surface of the pancreatic head (no. 13), LNs along the superior mesenteric vein (no...
June 5, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28584889/associations-between-early-tumor-shrinkage-and-depth-of-response-and-clinical-outcomes-in-patients-treated-with-1st-line-chemotherapy-for-advanced-gastric-cancer
#7
Hiroki Osumi, Daisuke Takahari, Eiji Shinozaki, Keisho Chin, Mariko Ogura, Takeru Wakatsuki, Takashi Ichimura, Izuma Nakayama, Tomohiro Matsushima, Kensei Yamaguchi
BACKGROUND: Although early tumor shrinkage (ETS) predictions of the efficacy and depth of response (DpR) reflects clinical outcomes in chemotherapy with epidermal growth factor receptor inhibitor regimens to treat metastatic colorectal cancer, their value in assessing treatments for advanced gastric cancer (AGC) is unclear. Here we evaluated relationships between ETS and DpR and clinical outcomes in AGC patients treated with first-line chemotherapy. METHODS: We retrospectively enrolled 612 consecutive patients treated with first-line chemotherapy for AGC between January 2010 and June 2016...
June 5, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28577229/automated-histological-classification-of-whole-slide-images-of-gastric-biopsy-specimens
#8
Hiroshi Yoshida, Taichi Shimazu, Tomoharu Kiyuna, Atsushi Marugame, Yoshiko Yamashita, Eric Cosatto, Hirokazu Taniguchi, Shigeki Sekine, Atsushi Ochiai
BACKGROUND: Automated image analysis has been developed currently in the field of surgical pathology. The aim of the present study was to evaluate the classification accuracy of the e-Pathologist image analysis software. METHODS: A total of 3062 gastric biopsy specimens were consecutively obtained and stained. The specimen slides were anonymized and digitized. At least two experienced gastrointestinal pathologists evaluated each slide for pathological diagnosis...
June 2, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28577228/role-of-hepatectomy-in-gastric-cancer-with-multiple-liver-limited-metastases
#9
Hiromichi Shirasu, Takahiro Tsushima, Masahiro Kawahira, Sadayuki Kawai, Takeshi Kawakami, Yosuke Kito, Yukio Yoshida, Satoshi Hamauchi, Akiko Todaka, Tomoya Yokota, Nozomu Machida, Kentaro Yamazaki, Akira Fukutomi, Yusuke Onozawa, Masanori Terashima, Katsuhiko Uesaka, Hirofumi Yasui
BACKGROUND: Several studies have demonstrated the benefit of hepatectomy for treating gastric cancer (GC) with liver-limited metastases (LLM). The survival benefit of hepatectomy compared with that of systemic chemotherapy is unknown, particularly in patients with multiple LLM. This study investigated the survival benefit of hepatectomy compared with that of systemic chemotherapy administered to patients with GC with multiple LLM. METHODS: We retrospectively reviewed the data of consecutive patients with GC with two or three LLM who underwent hepatectomy or received systemic chemotherapy as initial treatment at the Shizuoka Cancer Center between December 2004 and December 2015...
June 2, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28573357/clinical-significance-of-overexpression-of-nrg1-and-its-receptors-her3-and-her4-in-gastric-cancer-patients
#10
Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee
BACKGROUND: Neuregulin 1 (NRG1), a ligand for human epidermal growth factor (HER) 3 and HER4, can activates cell signaling pathways to promote carcinogenesis and metastasis. METHODS: To investigate the clinicopathologic significance of NRG1 and its receptors, immunohistochemistry was performed for NRG1, HER3, and HER4 in 502 consecutive gastric cancers (GCs). Furthermore, HER2, microsatellite instability (MSI), and Epstein-Barr virus (EBV) status were investigated...
June 1, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28567549/minimally-invasive-surgery-for-advanced-gastric-cancer-are-we-sure
#11
LETTER
L Graziosi, E Marino, A Donini
No abstract text is available yet for this article.
May 31, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28540637/importance-of-human-peritoneal-mesothelial-cells-in-the-progression-fibrosis-and-control-of-gastric-cancer-inhibition-of-growth-and-fibrosis-by-tranilast
#12
Hiroto Saito, Sachio Fushida, Shinichi Harada, Tomoharu Miyashita, Katsunobu Oyama, Takahisa Yamaguchi, Tomoya Tsukada, Jun Kinoshita, Hidehiro Tajima, Itasu Ninomiya, Tetsuo Ohta
BACKGROUND: Scirrhous gastric cancer is an intractable disease with a high incidence of peritoneal dissemination and obstructive symptoms (e.g., ileus, jaundice, and hydronephrosis) arising from accompanying marked fibrosis. Microenvironmental interactions between cancer cells and cancer-associated fibroblasts are the suggested cause of the disease. We elucidated the mechanisms of tumor growth and fibrosis using human peritoneal mesothelial cells (HPMCs) and investigated the effects of tranilast treatment on cells and a xenograft mouse model of fibrosis...
May 24, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28497176/five-weekly-s-1-plus-cisplatin-therapy-combined-with-trastuzumab-therapy-in-her2-positive-gastric-cancer-a-phase-ii-trial-and-biomarker-study-wjog7212g
#13
Yuji Miura, Yasutaka Sukawa, Shuichi Hironaka, Misuzu Mori, Kazuhiro Nishikawa, Shinya Tokunaga, Hiroyuki Okuda, Takeshi Sakamoto, Keisei Taku, Kazuo Nishikawa, Toshikazu Moriwaki, Yuji Negoro, Yutaka Kimura, Keita Uchino, Katsunori Shinozaki, Hiroharu Shinozaki, Nobuyuki Musha, Hirotsugu Yoshiyama, Takashi Tsuda, Yoshinori Miyata, Naotoshi Sugimoto, Tsuyoshi Shirakawa, Miki Ito, Kimio Yonesaka, Kenichi Yoshimura, Narikazu Boku, Katsuhiko Nosho, Toshimi Takano, Ichinosuke Hyodo
BACKGROUND: Five-weekly S-1 plus cisplatin (SP) therapy is the standard care for advanced gastric or esophagogastric junction cancer (GC/EGJC) in East Asia. However, its efficacy and safety when combined with trastuzumab therapy for human epidermal growth factor receptor 2 (HER2)-positive advanced GC/EGJC remains unclear. METHODS: Patients received 5-weekly SP therapy (S-1 at 40-60 mg twice daily for 21 days plus cisplatin at 60 mg/m(2) on day 8, every 5 weeks) plus trastuzumab therapy (first dose of 8 mg/kg, then 6 mg/kg every 3 weeks)...
May 11, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28493075/microrna-1-acts-as-a-tumor-suppressor-microrna-by-inhibiting-angiogenesis-related-growth-factors-in-human-gastric-cancer
#14
Meng Xie, Dafydd Alwyn Dart, Ting Guo, Xiao-Fang Xing, Xiao-Jing Cheng, Hong Du, Wen G Jiang, Xian-Zi Wen, Jia-Fu Ji
BACKGROUND: We recently reported that miR-1 was one of the most significantly downregulated microRNAs in gastric cancer (GC) patients from The Cancer Genome Atlas microRNA sequencing data. Here we aim to elucidate the role of miR-1 in gastric carcinogenesis. METHODS: We measured miR-1 expression in human GC cell lines and 90 paired primary GC samples, and analyzed the association of its status with clinicopathological features. The effect of miR-1 on GC cells was evaluated by proliferation and migration assay...
May 10, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28484889/the-value-of-diagnostic-endoscopic-submucosal-dissection-for-patients-with-clinical-submucosal-invasive-early-gastric-cancer
#15
Keiichi Fujiya, Kohei Takizawa, Masanori Tokunaga, Noboru Kawata, Makoto Hikage, Rie Makuuchi, Yutaka Tanizawa, Etsuro Bando, Taiichi Kawamura, Masaki Tanaka, Naomi Kakushima, Hiroyuki Ono, Masanori Terashima
BACKGROUND: The standard treatment for clinical submucosal invasive (cT1b) early gastric cancer is gastrectomy. However, Japanese gastric cancer treatment guidelines list endoscopic submucosal dissection (ESD) as an option for treating limited early gastric cancer cases. ESD can be curative depending on the pathological characteristics of resected specimens. Thus, we aimed to clarify the benefits and disadvantages of preceding ESD for early gastric cancer. METHODS: We retrospectively analyzed patients who underwent ESD or curative gastrectomy for cT1b gastric cancer with differentiated adenocarcinoma 30 mm or less in diameter...
May 8, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28477106/sarcopenia-in-gastric-cancer-when-the-loss-costs-too-much
#16
REVIEW
Elena Ongaro, Vanessa Buoro, Marika Cinausero, Riccardo Caccialanza, Annalisa Turri, Valentina Fanotto, Debora Basile, Maria Grazia Vitale, Paola Ermacora, Giovanni Gerardo Cardellino, Laura Nicoletti, Lorenzo Fornaro, Andrea Casadei-Gardini, Giuseppe Aprile
Sarcopenia is a complex syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength. Malignancy is a major determinant of sarcopenia, and gastric cancer (GC) is among the most common causes of this phenomenon. As sarcopenia is a well-recognized poor prognostic feature in GC and has been associated with worse tolerance of surgical and medical treatments, members of the multidisciplinary team should be aware of the clinical relevance, pathogenic mechanisms, and potential treatments for this syndrome...
May 5, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28474257/a-cumulative-effect-involving-malfunction-of-the-pth1r-and-atp4a-genes-explains-a-familial-gastric-neuroendocrine-tumor-with-hypothyroidism-and-arthritis
#17
Oriol Calvete, Maite Herraiz, Jose Reyes, Ana Patiño, Javier Benitez
BACKGROUND: Type I gastric neuroendocrine tumors (gNETs) classically arise because of hypergastrinemia and involve destruction of parietal cells, which are responsible for gastric acid secretion through the ATP4A proton pump and for intrinsic factor production. METHODS: By whole exome sequencing, we studied a family with three members with gNETs plus hypothyroidism and rheumatoid arthritis to uncover their genetic origin. RESULTS: A heterozygous missense mutation in the ATP4A gene was identified...
May 4, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28466360/phase-1-study-of-sulfasalazine-and-cisplatin-for-patients-with-cd44v-positive-gastric-cancer-refractory-to-cisplatin-epoc1407
#18
Kohei Shitara, Toshihiko Doi, Osamu Nagano, Miki Fukutani, Hiromi Hasegawa, Shogo Nomura, Akihiro Sato, Takeshi Kuwata, Kai Asai, Yasuaki Einaga, Kenji Tsuchihashi, Kentaro Suina, Yusuke Maeda, Hideyuki Saya, Atsushi Ohtsu
A previous dose-escalation study of sulfasalazine (SSZ), an inhibitor of cystine-glutamate exchange transporter xc (-), in the variant form of CD44 (CD44v)-positive cancer stem cells (CSCs) suggested that administration of SSZ induces the reduction of CD44v-positive cells and intracellular reduced glutathione (GSH) levels in patients with advanced gastric cancer (AGC). Here we report a study to evaluate SSZ in combination with cisplatin in patients with CD44v-expressing AGC refractory to cisplatin. SSZ was given by oral administration four times daily with 2 weeks on and 1 week off...
May 2, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28417260/five-year-survival-analysis-of-surgically-resected-gastric-cancer-cases-in-japan-a-retrospective-analysis-of-more-than-100-000-patients-from-the-nationwide-registry-of-the-japanese-gastric-cancer-association-2001-2007
#19
Hitoshi Katai, Takashi Ishikawa, Kohei Akazawa, Yoh Isobe, Isao Miyashiro, Ichiro Oda, Shunichi Tsujitani, Hiroyuki Ono, Satoshi Tanabe, Takeo Fukagawa, Souya Nunobe, Yoshihiro Kakeji, Atsushi Nashimoto
BACKGROUND: The aim of this retrospective study was to investigate the tumor characteristics, surgical details, and survival distribution of surgically resected cases of gastric cancer from the nationwide registry of the Japanese Gastric Cancer Association. METHODS: Data from 118,367 patients with primary gastric carcinoma who underwent resection between 2001 and 2007 were included in the survival analyses. The 5-year survival rates were calculated for various subsets of prognostic factors...
April 17, 2017: Gastric Cancer
https://www.readbyqxmd.com/read/28409418/polymorphisms-in-cars-are-associated-with-gastric-cancer-risk-a-two-stage-case-control-study-in-the-chinese-population
#20
Tian Tian, Ling Xiao, Jiangbo Du, Xun Zhu, Yayun Gu, Na Qin, Caiwang Yan, Li Liu, Hongxia Ma, Yue Jiang, Jiaping Chen, Hao Yu, Juncheng Dai
BACKGROUND: The cysteinyl transfer RNA synthetase gene (CARS) is located on chromosome band 11p15.5, which is an important tumor-suppressor gene region. Mutations in CARS have been identified in many kinds of cancers; however, evidence for a relationship between genetic variants in CARS and gastric cancer at the population level is still lacking. Thus, we explored the association of variants in CARS with gastric cancer using a two-stage case-control strategy in Chinese. METHODS: We undertook a two-stage case-control study to investigate the association between polymorphisms in CARS and risk of gastric cancer with use of an Illumina Infinium(®) BeadChip and an ABI 7900 system...
April 13, 2017: Gastric Cancer
journal
journal
34638
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"